We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Stockholm, Sweden

ESTRO 2026

Session

Sunday
May 17
14:10 - 15:10
A1 Plenary
Highlights: Latest Trials - Prostate
Barbara Alicja Jereczek-Fossa, Italy
Proffered Papers
Interdisciplinary
14:10 - 14:19
Pelvic radiotherapy in patients with very high-risk localized prostate cancer: results of the PEACE 2 phase III randomized trial
Pierre Blanchard, France
-5520
14:19 - 14:20
Acute toxicity in PACE-NODES: A randomised trial of 5 fraction (f) prostate stereotactic body radiotherapy (SBRT) vs 5f prostate and pelvic nodal SBRT
Angela Pathmanathan, United Kingdom
-5560
14:28 - 14:37
Conventional vs Pelvic Ultra-Hypofractionated IMRT with HDR Brachytherapy in Prostate Cancer: Early Outcomes from PCS-XI Complete Cohort(NCT05820633).
François Fabi, Canada
-2468
14:37 - 14:46
Discussant
Łukasz Kuncman, Poland
14:46 - 14:55
DART: Darolutamide Added to Radiotherapy — A Randomised Phase II Trial of SBRT With or Without Darolutamide for Oligorecurrent Prostate Cancer
Piet Ost, Belgium
-5541
14:55 - 15:04
HERMES: 2-year outcomes of a randomised phase II trial of 2-fraction and 5-fraction MRI-guided adaptive radiotherapy for prostate cancer
Sian Cooper, United Kingdom
-5479
15:04 - 15:10
Discussant
Pervin Hurmuz, Turkey